IperionX Ltd. IPX
Spruce Point shorts IperionX: its 'revolutionary' HAMR titanium process is unlikely to displace 70-year Kroll, customers are absent, and the $1.2bn market cap implies 70-95% downside risk.
Thesis
IperionX, a $1.2 billion specialty metals company formerly named TAO Commodities and Hyperion Metals, claims its 'revolutionary' HAMR process can reshore the U.S. titanium supply chain by converting ore or scrap into low-cost powder. Spruce Point argues the IP — acquired cheaply from the University of Utah after Alcoa and Boeing reportedly passed — is energy-inefficient and unlikely to displace the 70-year Kroll process, while the titanium powder market is already 3.5x oversupplied and IPX has booked virtually no revenue despite years of partnership announcements. They flag financial reporting discrepancies (Titan acreage, capex, G&A, headcount), a CEO who quintupled pledged shares without SEC disclosure, and a $99m IDIQ Army contract obligating only $1.3m. Trading at 24x 2026E revenue versus 1.4x peer median, IPX has 70-95% downside to tangible book value.
SCQA
IperionX (Nasdaq/ASX: IPX), formerly TAO Commodities and Hyperion Metals, is a $1.2bn pre-revenue specialty metals story promising to reshore the U.S. titanium supply chain via its acquired 'HAMR' powder process and Tennessee Titan mining project.
Spruce Point's forensic review finds HAMR is energy-inefficient and unlikely to displace Kroll, the powder market is already 3.5x oversupplied, customers and offtake are absent, and reporting discrepancies span capex, acreage, G&A and headcount.
Investors should short the stock and exercise skepticism: management has rebranded three times without delivering revenue, the CEO quintupled pledged shares without SEC disclosure, and internal controls warrant doubt rather than the consensus Buy rating.
Valued on price-to-tangible-book like distressed peers (0.5x-1.0x) instead of the current 24x 2026E revenue multiple, IPX is worth roughly $1.50-$10.71 per share versus $36.51, implying 70-95% downside.
The three reasons
- 1
HAMR titanium process is energy-inefficient and unlikely to displace the 70-year Kroll process
- 2
Titanium powder market is already 3.5x oversupplied with capacity exceeding shipments
- 3
IPX trades at 24x 2026E revenue vs 1.4x peer median — 70-95% downside to tangible book
Primary demands
- Investors should exercise caution and recognize 70-95% downside risk
- IPX should clarify reporting discrepancies in Titan acreage, capex, G&A and headcount
- CEO should make corresponding SEC disclosure of the 5x increase in pledged shares
- Auditor (PwC) engagement partner should be relocated from Perth to Charlotte where assets are located
KPIs cited
Pattern membership
Precedents cited
- Piedmont Lithium (Nasdaq/ASX: PLL) — short-seller allegations and collapse
- Paringa Resources (now Terra Metals) — IPX management's prior failed venture
- Coalspur Mines — IPX management's prior failed venture
- Proterra Inc. (Nasdaq: PTRA) — SPAC bankruptcy where IPX's CFO was VP Finance
Composition what's on the 93 slides
Slide gallery ·
Notes
Classic Spruce Point short report on IperionX (IPX), a promotional pre-revenue titanium reshoring story. Cover slide uses a creative three-persona framing (Scientist/Businessman/Skeptical Investor) overlaid on a plant photo. Heavy use of red highlight callouts, hyperlinked sourcing, and embedded primary-source artifacts (FOIA responses, ASX vs SEC filing comparisons, expert interview transcripts). Argues by analogy to Piedmont Lithium (same management adviser overlap) and prior failed mining ventures. Genre is short_seller / fraud_exposure-adjacent: focus is on commercial viability + reporting discrepancies + valuation premium rather than outright fraud allegation. No SOP — instead uses scenario-based price-to-tangible-book downside math.